Objective <p>To describe the effects of dexmedetomidine on sedation, pain, respiratory status, and hemodynamics in neonates.</p> Methods <p>A retrospective study of 206 infants in a level IV NICU (2016–2021) receiving continuous dexmedetomidine infusion. Pain/sedation scores, BP, vasopressor and inotrope score (VIS), and concomitant sedatives/analgesics (CSA) were recorded before and every 3–4 h for 24 h.</p> Results <p>Median PMA:32 weeks. Hypotension occurred in 26%, primarily in infants &lt;32weeks PMA, correlating with higher VIS and CSA. CSA use significantly predicted vasopressors/inotrope use.</p> Conclusion <p>Dexmedetomidine, with CSA, increases cardiovascular instability in preterm infants who have unique myocardial structure and function and therefore higher vulnerability.</p> Clinical Trial Registration (if any) <p>None (not applicable).</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Dexmedetomidine’s effect on neonatal sedation, pain, respiratory status and cardiovascular system

  • Marjorie M. Makoni,
  • Ivonne Sierra-Strum,
  • Adrianne R. Bischoff,
  • Jamie L. Miller,
  • Lise DeShea,
  • William Howard Beasley,
  • Edgardo Szyld

摘要

Objective

To describe the effects of dexmedetomidine on sedation, pain, respiratory status, and hemodynamics in neonates.

Methods

A retrospective study of 206 infants in a level IV NICU (2016–2021) receiving continuous dexmedetomidine infusion. Pain/sedation scores, BP, vasopressor and inotrope score (VIS), and concomitant sedatives/analgesics (CSA) were recorded before and every 3–4 h for 24 h.

Results

Median PMA:32 weeks. Hypotension occurred in 26%, primarily in infants <32weeks PMA, correlating with higher VIS and CSA. CSA use significantly predicted vasopressors/inotrope use.

Conclusion

Dexmedetomidine, with CSA, increases cardiovascular instability in preterm infants who have unique myocardial structure and function and therefore higher vulnerability.

Clinical Trial Registration (if any)

None (not applicable).